44 results about "Dendrite" patented technology

This application relates to the field of tumor treatment technology, specifically to a drug combination and evaluation method for improving the sensitivity of MSS CRC to anti-PD-1 / PD-L1 therapy. The drug combination comprises vancomycin and an immune checkpoint inhibitor. Vancomycin is used to remodel the gut microbiota and reduce L-asparagine levels; the immune checkpoint inhibitor is used to activate CD8. + T-cell anti-tumor response. By combining vancomycin with immune checkpoint inhibitors, the antigen-presenting capacity of dendritic cells is enhanced, thereby increasing the sensitivity of MSS CRC to anti-PD-1 or anti-PD-L1 immunotherapy. This application focuses on the upstream initiation link of gut microbiota-metabolites-dendritic cells-immune activation, relieving the inhibition of dendritic cell antigen presentation by L-asparagine and enhancing CD8+. + T cell activation and tumor immune response enhance the sensitivity of MSS-type colorectal cancer to anti-PD-1 / PD-L1 therapy.

This invention relates to a self-adjuvanted biomimetic lipid nanoparticle, its microfluidic assembly method, and its anti-tumor applications. The self-adjuvanted biomimetic lipid nanoparticle has a structure in which an activated dendritic cell membrane (ADCM) is coated on the surface of a lipid nanoparticle (LNP) loaded with mRNA. The advancements of this invention compared to traditional LNPs are: the self-adjuvanted biomimetic lipid nanoparticle (ADCM-LNP) exhibits a faster cellular uptake rate and higher transfection efficiency, thereby inducing a strong Th1-type immune response and a potent CTL-mediated tumor-killing effect. In vivo biodistribution studies have shown that this system exhibits significant spleen-targeting (splenic tropism) and demonstrates excellent therapeutic efficacy in a HER2-positive breast cancer model.

The present invention provides for chimeric antigen receptor constructs capable of being expressed in dendritic cells (DCs), and DCs modified to express one or more chimeric antigen receptors (CARs) as well as compositions comprising these modified DCs and methods of stimulating an adaptive immune response in a subject. The intracellular domain of the CAR comprises a toll-interleukin receptor (TIL) intracellular signalling domain and a costimulating domain selected from CD3 signalling domain, CD28 signalling domain and a combined CD28 and CD3 signalling domain.

The application relates to an aptamer-membrane fusion liposome nanomedicine as well as a preparation method and application thereof, and belongs to the technical field of nanomedicine preparation. The aptamer-membrane fusion liposome nanomedicine disclosed by the application is formed based on the affinity between the cholesterol (Chol) at the 3' end of an aptamer and a liposome, has small bond energy, good spatial orientation, high selectivity and reversibility. In the aptamer-membrane fusion liposome nanomedicine, the liposome can be fused with a membrane, co-loaded auranofin (AUR) has the functions of promoting cell iron death and sensitizing radiotherapy, the immunoadjuvant aptCpG can target dendritic cells (DCs), stimulate the functions of DCs maturation and antigen presentation, and further activate subsequent immune responses. The bionic liposome nanomedicine provides a new way for improving the effectiveness of clinical malignant tumor treatment.

The application provides an application of a hair follicle immune homeostasis regulation strategy in treating alopecia diseases. A group of pathological LAMP3 + CCR7 + IL4I1 + DC3 dendritic cell subpopulation. A DC3 dendritic cell subpopulation marker gene Il4i1 Drive conditionally knockout one of the CGRP receptor complexes Calcrl The constructed spontaneous alopecia areata animal model can well simulate the progressive and active hair loss of alopecia areata patients, form stable hair loss patches, and combine with pathological changes such as hair follicle immune cell infiltration, which indicates that the dendritic cell CGRP signal loss is an important inducement for mediating systemic alopecia areata. The application also discloses a pharmaceutical composition or kit for preparing a drug for relieving / treating hair loss, improving hair follicle homeostasis, or enhancing hair growth / black coloration (reducing white hair), which comprises: (a) a JAK kinase inhibitor, and (b) a neuropeptide CGRP or a receptor agonist thereof.

Provided herein are chimeric antigen receptors, comprising an extracellular domain capable of binding to an antigen, an Fc region, a flexible linker, a transmembrane domain, and may further comprise at least one intracellular domain that is designed to increase the anti-tumor activities of granulocytes, macrophages, and dendritic cells by increasing their phagocytosis and / or proinflammatory cytokines secretion and / or antigen presentation. Provided herein are vectors and nucleic acid molecules encoding any of the chimeric antigen receptors described herein. Provided herein are methods to genetically engineer granulocyte-macrophage progenitors (GMPs) to express the chimeric antigen receptors described herein. The CAR-Fc-GMPs may be induced to differentiate into macrophages or granulocytes. Provided herein are macrophages and granulocytes that express a CAR-Fc prepared by any of the methods described herein. Provided herein is an immunotherapy method for treating a subject having cancer with GMPs or macrophages or granulocytes that express the chimeric antigen receptors described herein.

Methods of treating diseases associated with pathologic neuronal cells are provided. Accordingly, there is provided a method of treating a disease associated with pathologic neuronal cells characterized by aberrant excitability comprising: (a) administering into a first neural region of the subject a therapeutically effective amount of a polynucleotide encoding a bistable type II opsin attached to a heterologous ER export signal and / or membrane trafficking signal which enables trafficking of said bistable type II opsin to axon and / or dendrite terminals, wherein said first neural region comprises cell bodies of said pathologic neuronal cells; and (b) exposing a second neural region of said subject to light in a wavelength that activates said bistable type II opsin, wherein said second neural region comprises axon or dendrite terminals of said pathologic neuronal cells associated with a symptom of said disease, and wherein said first neural region and said second neural region are distinct.

The application discloses a cell PD-L1 glycosylation in-situ visualization and biological function research method based on hybridization chain reaction. The application adopts a hybridization chain reaction strategy (HCR) of a logic "AND" gate activated by nucleic acid aptamer recognition and metabolic glycan labeling, and constructs a new method for a cell PD-L1 glycosylation in-situ visualization and biological function research method. Through HCR signal amplification induced by adjacent double recognition, the detection sensitivity of PD-L1 glycosylation on different cells is significantly improved, and subtle fluctuations in the PD-L1 glycosylation level can be accurately captured, so as to provide an analysis tool for revealing the dynamic changes under different physiological or pathological conditions. Meanwhile, the application first clarifies the immune regulation function of the PD-L1 glycosylation of dendritic cells, and further expands the research scope of tumor immune checkpoints.

This invention discloses a GPU-based neuronal skeleton extraction method based on topology-simplified trunk growth, relating to the fields of neuroinformatics and 3D biomedical image processing. The method includes: threshold filtering and denoising of the input volume data, and retaining the largest connected component based on 3D connected component labeling to remove isolated noise; given the cell body center coordinates, determining the cell body region through spherical expansion and removing it from the foreground to highlight neural protrusions such as dendrites and axons; after obtaining the coarse skeleton, using GPU to perform topology simplification, and constructing a path scoring function combining path length and average normalized brightness, iteratively selecting and retaining the trunk path with the best score, enhancing trunk continuity and suppressing pseudo-branches caused by noise and breaks. This invention can achieve robust skeleton extraction in 3D data with noise interference and uneven brightness, and is suitable for applications such as neuronal morphology reconstruction and quantitative analysis.

This invention relates to the field of neural network architecture search and industrial intelligent processing technology, and discloses a structure search method for multi-output dendritic neuron models for industrial classification tasks. The method includes: initializing the synaptic connection weights and dendritic threshold parameters of the multi-input multi-output dendritic neuron model to generate an initial population; uniformly dividing the initial population into several subpopulations of equal size; calculating the temporal and spatial criteria for each subpopulation after task allocation and optimization, and dynamically allocating evolutionary computational resources for each subpopulation based on the fitness change rate represented by the temporal criterion and the population distribution state represented by the spatial criterion; implementing an accelerated sharing penalty mechanism to adjust fitness values ​​according to the crowding degree among individuals to maintain solution set diversity; and updating each subpopulation. This invention solves the problem of low convergence efficiency caused by uniform resource allocation in traditional large-scale multi-objective evolutionary algorithms during neural network architecture search.

The invention discloses a method for observing the shape and number of synapses in a dentate gyrus region based on image analysis, and relates to the technical field of neurobiology. The method comprises the following steps: S1, tissue treatment: after an experimental animal is anesthetized, pouring a buffer solution and a stationary solution into the heart in stages, separating hippocampus tissue, trimming and fixing, pre-cooling, slicing and preserving at low temperature; s2, dyeing and marking: performing targeted marking on the dentate gyrus area of the sea horse by adopting DiI particles through a fine tungsten steel through needle, and preserving at low temperature after incubation; s3, fixing and mounting: fixing for the second time, and mounting with an anti-fluorescence quenching agent after DAPI nuclear dyeing; s4, confocal imaging is carried out, exclusive parameter layer scanning is set, and qualified dendritic spine images are screened; and image quantitative analysis can be further carried out, and accurate quantification is realized according to classification standards. The method is standard in operation, greatly improves sample quality and experimental result credibility, optimizes experimental efficiency and controllability and reduces technical threshold by means of targeted marking and standardized processes, and is suitable for relevant basis and application research of the hippocampal synapses.

This invention discloses a panel for detecting histiocytic / dendritic cell tumors based on 10-color multiparameter flow cytometry and its applications. The panel is composed of the following antibodies: CD4, HLA-DR, CD45, CD1c, CD207, CD123, CD56, CD1a, CD3, and CD14. The flow cytometry protocol provided by this invention enables rapid, objective, and quantitative analysis of large numbers of cells, and is particularly suitable for detecting small tumor populations in mixed cell populations or assessing the heterogeneity of antigen expression. This is an important supplement to existing pathological diagnostic systems and provides key evidence for precision medicine.

Provided is a novel gel-type microneedle patch for treating melanoma, which is loaded with dendritic cells (DC) and paclitaxel (PTX). The chemotherapeutic drug paclitaxel utilizes its own toxicity to

The application relates to the technical field of brain science image processing, and discloses a brain tissue neuron morphology three-dimensional reconstruction and connection group analysis method and system. The method comprises the following steps: feature point extraction and matching and optical flow registration are performed on continuous ultrathin section electron microscope images to obtain three-dimensional image body data; a three-dimensional deep convolutional neural network is used for semantic segmentation of cell bodies, dendrites, axons and dendritic spines, and secondary registration is driven through confidence feedback; synapses are detected and classified into excitatory or inhibitory types; topological perception skeletonization reconstruction is performed, and segmentation correction is constrained through topological anomaly feedback; and a synapse connection matrix is constructed, and graph theory analysis is performed.

The application belongs to the technical field of antitumor drugs, and particularly relates to a nanofiber hydrogel for synergistic antitumor sonodynamic / chemodynamic therapy, a preparation method and application thereof, synthesis of Nap-Pept, preparation of Nap-Pept / Fe 3+ / Cur nanogel, under ultrasonic conditions, synergistic sonodynamic therapy of a traditional Chinese medicine sonosensitizer Cur and Fe 3+ mediated chemodynamic therapy, triggering immunogenic death of cancer cells by increasing ROS levels of B16F10 cells and then damaging mitochondrial function. Nap-Pept / Fe 3+ / Cur@US promotes expression of the immune-related factor calnexin, release of high mobility group protein 1 and maturation of dendritic cells to kill tumor cells, thereby exerting an antitumor effect. In vivo and in vitro studies show that the anticancer effect of the combined sonodynamic and chemodynamic therapy is superior to that of single therapy, achieving the purpose of precise and efficient anti-melanoma.

This invention discloses a DC-specific knockout animal model of the Adamdec1 gene, its construction method, and its applications. The method involves inserting Loxp sites at both ends of exons 2–10 of the Adamdec1 gene to obtain the Adamdec1 gene. flox / flox Mice, then with Cd11c cre / + Mouse hybridization and screening to obtain Cd11c cre / + Adamdec1 flox / flox In mice, the Adamdec1 gene was specifically knocked out in dendritic cells. This model, induced by 3% DSS, exhibited a more severe colitis phenotype and can be used to establish a stable and reliable research model for acute colitis. This invention provides a precise tool for studying the function of Adamdec1 in intestinal immune regulation and has significant scientific and translational value.

This disclosure provides methods for producing neutrophils under serum-free and feeder-free conditions from protein tyrosine phosphatase 1B (PTP1b)-inhibited pluripotent stem cells. The disclosure further provides PTP1b inhibited neutrophils and uses thereof. Also disclosed are methods for producing human neutrophil-DC hybrid cells and human neutrophil-DC hybrid cells produced thereby.

The application discloses a PGPC / CpG combined adjuvant and a method and application thereof for improving the efficiency of a type I dendritic cell anti-tumor vaccine, and belongs to the technical field of biotechnology. The method for improving the efficiency of the type I dendritic cell anti-tumor vaccine by using the PGPC / CpG combined adjuvant disclosed by the application stimulates cDC1 by using the PGPC / CpG combined adjuvant; the final concentration of the CpG is 1 mM, and the final concentration of the PGPC is 25 µg / mL. The PGPC / CpG combined adjuvant can significantly promote the expression of the co-stimulating molecules CD40, CD80, CD86 on the surface of cDC1, and inflammatory factors IL-12, TNFɑ and IL-1β, enhance the ability of the cDC1 to induce CD8 + T cell activation, proliferation and differentiation into anti-tumor effector T cells, and effectively improve the in-vivo anti-tumor effect of the cDC1 vaccine.

The application discloses a photovoltaic power prediction method based on an attention dendritic neural network, and belongs to the technical field of photovoltaic power generation. The method comprises the following steps: photovoltaic power time sequence construction and amplitude constraint processing, time-dependent feature window construction, grouping mapping modeling of dendritic branches, attention modulation mechanism based on response intensity, fluctuation perception membrane potential modulation, photovoltaic power prediction output, prediction result constraint and application, non-negativity and capacity constraints are applied to the prediction result, and finally, the prediction result can be used for power grid dispatching, energy storage control and photovoltaic power station operation management. The method realizes high-precision and high-stability prediction of photovoltaic power, and improves the engineering adaptation ability of the method.

This invention discloses a 25-(OH)VD3 molecularly imprinted electrochemical sensor based on a three-dimensional dendritic gold nanoassembly, its preparation method, and its application. The preparation method includes: modifying an electrode surface with a three-dimensional dendritic gold nanoassembly to obtain an electrode modified with the three-dimensional dendritic gold nanoassembly; and, using p-phenylenediamine and resorcinol as bifunctional monomers and 25-(OH)VD3 as a template molecule, electropolymerizing the electrode surface modified with the three-dimensional dendritic gold nanoassembly using cyclic voltammetry to form a molecularly imprinted film, followed by removing the template molecule to obtain the 25-(OH)VD3 molecularly imprinted electrochemical sensor. The method for detecting 25-(OH)VD3 using the 25-(OH)VD3 molecularly imprinted electrochemical sensor based on a three-dimensional dendritic gold nanoassembly prepared by this invention has advantages over existing methods such as high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS / MS) and fluorescence methods, including lower cost, easier preparation, convenient operation, and higher sensitivity. Furthermore, this invention provides a new approach and method for detecting abnormal vitamin D metabolism in humans, and has strong practical application.

This invention discloses a method for constructing a type I classical dendritic cell-specific knockout Dyrk1a gene mouse model and its application. The method includes the following steps: (1) [The text abruptly ends here, likely due to an incomplete sentence or missing information.] flox / + Donor mice were crossed with XCR1-Cre positive tool mice, and the genotype Dyrk1a was obtained through screening. flox / + XCR1-Cre+ and Dyrk1a flox / + (2) The F1 generation hybrid offspring of XCR1-Cre- were crossbred; (3) The F1 generation hybrid offspring obtained in step (1) were crossbred with siblings or backcrossed to obtain the F2 generation population; (4) The F2 generation population obtained in step (2) was identified and screened for genotype Dyrk1a. flox / flox Individuals with XCR1-Cre+ are thus established. This invention overcomes the embryonic lethality limitation caused by whole-body Dyrk1a knockout, and for the first time achieves in-depth research on the long-term regulatory mechanism of Dyrk1a in the cDC1 subpopulation in adult live mice. This effect is achieved through the conditional design of the Cre-loxP system, avoiding early developmental disorders and providing a reliable genetic tool for elucidating immune system function, significantly expanding the applicability of the research.

This invention provides a method, system, and readable storage medium for real-time measurement of secondary dendrite spacing based on a high-temperature confocal microscope, comprising: S1: preparing a sample and placing it on the sample stage of a high-temperature confocal microscope, completing system linkage debugging and parameter setting; S2: subjecting the sample to heating, melting, and holding treatment, with the temperature control and cooling unit controlling the cooling rate, and simultaneously acquiring dynamic images of dendrite growth, temperature data, and cooling rate data; S3: performing image preprocessing and dendrite feature recognition, identifying the main dendrites and secondary dendrite arms, and removing interfering areas; S4: calculating the secondary dendrite spacing; S5: outputting the secondary dendrite spacing value and simultaneously plotting the corresponding curves of cooling rate, temperature, time, and secondary dendrite spacing, and archiving the data. This invention realizes in-situ observation of dendrite growth under different cooling rates during solidification and real-time, rapid, and stable measurement of secondary dendrite spacing.

A method for culturing dendritic cells by first proliferating them from peripheral blood and then differentiating them. Peripheral blood mononuclear cells obtained by isolation are proliferated in vitro with a cytokine composition (consisting of FLT-3L, TPO, SCF, IL3, IL6, and SR1) in the initial stage, and then differentiated (using a cytokine composition consisting of FLT-3L, GM-CSF, IL3, and TGF-β) to obtain cDC1 cells. Verification has shown that the method for preparing cDC1 cells in vitro according to the present invention is effective for the first 2.5 × 10 6 From PBMC to XCR1 + cDC1 cells can be obtained, and their number is at least 0.8 × 10⁶ 6 This represents 32% of PBMCs, which can meet the cell count needs required for clinical application.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic bacterial DNA nanomicelle, its preparation method, and its applications. By mimicking the structural and functional characteristics formed when microorganisms infect a host, exogenous nucleic acid stimulation signals and oxidative stress regulation functions are integrated into a single nanostructure. A micellar nanostructure is designed, comprising a complex of oligonucleotides containing CpG motifs and ferrocene groups, which is formed through self-assembly in solution. This nanomicelle can significantly promote the proliferation or differentiation of dendritic cells, improve their maturity, and enhance their immune activation capacity; by enhancing the cross-presentation capacity of dendritic cells to target antigens, it effectively promotes cytotoxic CD8+. + T-cell immune responses; it can also enhance the body's cellular immune response by inducing the activation and proliferation of antigen-specific cells. These DNA nanomicelles have significant clinical application value in areas such as vaccine adjuvants, tumor immunotherapy, and immune regulation.

The application discloses a target strategy and a drug intervention method for improving Primrose syndrome, and belongs to the technical field of biological medicine. The experiment proves that Momordin Ic can significantly improve the SUMO level of ZBTB20 in vitro cells or Primrose syndrome (PS) mice, can effectively improve the defects of reduced neuron dendritic branching in the hippocampal CA1 region of the PS mice in pathology, can enhance the complexity, and can improve the cognitive and emotional disorders such as memory impairment and anxiety-like behavior of the PS mice to different degrees in behavior. The application discloses that Momordin Ic can improve the PS-related neuropathological changes and behavioral cognitive defects by targeting the SENP1-ZBTB20-SUMO pathway, and provides a new candidate molecule and a clear action target for developing potential therapeutic drugs for Primrose syndrome.